Under construction – not a live service
Sign in
Taking people in FranceNo phase

Studies speech patterns to help detect early signs of schizophrenia

Uses computer analysis of speech to study people at high risk of psychosis.

Plain-language title generated from the registry record
Registry title: Semantic and Syntactic Computerized Analysis of Free Speech

Key facts

Where
Brest, Caen, and Paris, FranceSee the 3 sites

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 15 and 30 years old?

Source: NCT03525054, who can take part

Where in France

  • CHRU de BrestBrest, FranceTaking people
  • Meunier SophieCaen, FranceNot yet recruiting
  • CH de SAINT ANNEParis, FranceTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
University Hospital, Brest
Trial code
NCT03525054
Record updated
2 June 2026
Original description
Subtle speech disorganization could be predictive of a transition to schizophrenia of ultra-high-risk patients. The aim of our longitudinal multicenter cohort study is to identify specific linguistic markers of the psychotic transition to validate a french predictive model of this transition using computerized speech analysis techniquesRead full original descriptionShow less

Semantic and Syntactic Computerized Analysis of Free Speech

Subtle speech disorganization could be predictive of a transition to schizophrenia of ultra-high-risk patients. The aim of our longitudinal multicenter cohort study is to identify specific linguistic markers of the psychotic transition to validate a french predictive model of this transition using computerized speech analysis techniques

Inclusion: Major and/or minor from 15 to 30 years old; Who alleged a suicidal gesture or idea or behavior that has repercussions in their emotional, social or professional life; If patients receive neuroleptic treatment that impairs cognitive abilities, a one-week wash-out period will be scheduled prior to assessment; Affiliated with or beneficiary of a health insurance/social security system; Able and willing to provide written informed consent.

Exclusion: History of psychosis; Neurological disorder or major health problem; Risk of self-harm or violence not compatible with outpatient treatment; QI<70 (WAIS); Impossibility to interrupt neuroleptic treatment for one week; Refusal to participate.

ClinicalTrials.gov NCT03525054